Visium SA, a Swiss company specialized in artificial intelligence and data solutions for highly regulated industries, has closed its first institutional funding round, co-led by Columbus Venture Partners and Concentric.
The round also includes the participation of a selected group of unicorn founders and leaders from some of the most relevant AI and technology companies.
Founded in 2018 and headquartered in Lausanne, Visium has grown to a team of 100 AI experts across Europe and has delivered more than 250 AI and data solutions for global leaders in life sciences, specialty chemicals and other regulated industries. Its clients include Roche, Novartis and several top pharmaceutical companies, as well as specialty chemicals leaders such as dsm-firmenich.
Visium transforms critical business functions through an AI-native approach, redesigning workflows from first principles rather than simply optimizing existing processes. Its model combines strategy, advanced engineering, data science and deep expertise in regulated industries, enabling the company to design and deploy AI systems capable of operating in real-world, complex and highly demanding environments.
For Columbus Venture Partners, this investment responds to a clear thesis: generative AI is set to redefine structural processes across the pharmaceutical, biotechnology and clinical research industries. Its ability to design, automate and optimize complex workflows can reduce timelines, ease operational burden and accelerate data-driven decision-making.
In a sector where development timelines, operational efficiency and the quality of evidence are critical factors, solutions such as Visium’s can have a direct impact on time-to-market, R&D productivity and the overall profitability of the biomedical value chain.
“Our investment in Visium is driven by the clear thesis that generative AI is redefining operational processes across the pharmaceutical and biotechnology industries. Its ability to design, automate, and optimize complex workflows in an agile manner enables pharma companies, CROs, and R&D teams to significantly reduce timelines and the operational burden associated with drug development. Visium sits at the core of this transformation, removing structural bottlenecks and accelerating data-driven decision-making. These solutions not only enhance efficiency but also have a direct impact on time-to-market and overall sector profitability, fully aligning with our strategy of investing in technologies that catalyze innovation while delivering tangible value,” says Damià Tormo, General Partner at Columbus Venture Partners.
With this funding, Visium will accelerate its expansion across Europe and the United States, strengthen its team and scale its product capabilities to bring its solutions to a broader set of global companies.
As part of the transaction, Javier Fernández, Operating Partner at Columbus Venture Partners and former CEO of Vitro S.A., joins Visium’s Board of Directors, alongside Sam Bourton, co-founder of QuantumBlack; Denis Shafranik, co-founder and Partner at Concentric; and Urban Lankes, Chairman of biGENIUS and Coople Switzerland.
With this investment, Columbus Venture Partners reinforces its commitment to companies capable of turning scientific and technological innovation into real impact for industry, patients and the broader healthcare ecosystem.
cloud technology axon
Across all funds, MCP’s 13 portfolio companies delivered revenues of...
